Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

Ovarian cancer cells may quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better, a study published by Mayo Clinic researchers suggests.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior.

February 20, 2026

Vol.52 No.07

Clinical Trials & Tribulations

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Trials & Tribulations

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.

Otis Brawley looks back on a year of great science and greater challenges

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.

December 31, 2025

Clinical Roundup

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.

December 19, 2025

Vol.51 No.46

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

YOU MAY BE INTERESTED IN

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Otis Brawley looks back on a year of great science and greater challenges

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Renew today!

Subscriber content

Never miss an issue!

Login